NEW YORK (August, 15, 2024)—TB Alliance is honored to appoint Ann Taylor, MD to its Board of Directors.
Welcoming Dr. Taylor to the Board, David Norton, the Chairman of the TB Alliance Board, remarked, “As the deadliest infectious disease on the planet, TB is a global health emergency that requires leadership, innovative problem-solving and a commitment to bold action. Ann brings all of this – as evidenced by over four decades of broad leadership experience in the biopharmaceutical industry – to the TB Alliance Board. We look forward to working with and learning from her as we usher in new approaches to addressing this pandemic.”
Dr. Taylor added, “I’m thrilled to join the Board of the TB Alliance. Our global mission to enhance access to well-tolerated and quickly acting agents – building on great discovery and collaboration – will impact millions of people around the world.”
Dr. Taylor most recently oversaw the full range of clinical development activities as Chief Medical Officer of AstraZeneca. She has also held executive roles with MedImmune, Novartis Institute for BioMedical Research and Pfizer. Dr. Taylor is a Board-certified endocrinologist and earned her medical degree from Harvard Medical School. She serves on the Board of Directors of Comanche Biopharma, Unlearn.AI, Terns Pharmaceuticals, and Yleana Leadership Foundation.
Since 2000, TB Alliance has worked with partners around the world to end the global TB pandemic by ensuring that faster-acting, affordable treatments are accessible to every individual in need.